Clin Oncol | Volume 1, Issue 1 | Research Article | Open Access

Genistein Induced Apoptosis of Gastric Cancer Cell through Bcl-2 and Caspase-3 Regulation

Yusheng Li1#, Wei Luo1#, Guangxin Li2, Qing Liu1, Yanping Liu3* and Lichun Sun4*

1Department of Orthopedics, Xiangya Hospital, Central South University, China
2Department of Pathology, Chong Qing Cancer Institute, China
3Department of cell Biology, School of life Sciences, Central South University, China
4Department of Medicine, Tulane University Health Science Center, USA
#Equally Contributed

*Correspondance to: Yanping Liu Lichun Sun 

Fulltext PDF


Aim: To investigate the effects of genistein on cell apoptosis in the human gastric cancer cell BGC- 823 and the potential regulation pathway involved in its apoptotic effect.Methods: Effects of genistein on the proliferation, cell cycle progression and apoptosis of gastric cancer cells were examined in vitro. Western blotting were applied to analyze the proteins associated with the biological effects of genistein.Results: Gastric cancer cell growth was attenuated by genistein treatment in dose- and timedependent manner. Cell cycle progression analysis showed that apoptosis was enhanced in genistein treated cells and cell cycle arrest at G2/M phase. Increased apoptosis was accompanied by increased level of caspase-3 protein and decreased level of Bcl-2 protein.Conclusions: Genistein induce the apoptosis of BGC-823 in dose- and time-dependent manner. This apoptosis may be mediated by down-regulating the apoptosis-associated Bcl-2 gene and upregulating the expression of apoptosis-associated caspase-3 gene. As genistein was effective in vitro in promotion of apoptosis of gastric cancer cell by caspase-3 and Bcl-2 related apoptotic pathway, it might be a potential therapeutic agent against gastric cancer.


Genistein; Human gastric cancer; Apoptosis; Caspase-3; Bcl-2


Li Y, Luo W, Li G, Liu Q, Liu Y, Sun L. Genistein Induced Apoptosis of Gastric Cancer Cell through Bcl-2 and Caspase-3 Regulation. Clin Oncol. 2016; 1: 1150.

Subscribe to Our Newsletter